Epidermal growth factor receptor mutational status and brain metastases in non–small-cell lung cancer

Vijaya Raj Bhatt, Sanyo P. D’Souza, Lynette M. Smith, Allison M. Cushman-Vokoun, Vanita Noronha, Vivek Verma, Amit Joshi, Anuradha Chougule, Nirmala Jambhekar, Anne Kessinger, Alissa Marr, Vijay Patil, Sripad D. Banavali, Apar Kishor Ganti, Kumar Prabhash

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Introduction Epidermal growth factor receptor (EGFR) mutations in non–small-cell lung cancers (NSCLC) may be more common in patients with brain metastases. Previous studies, however, did not adjust for effects of confounding variables. Methods This retrospective study included 1,522 consecutive patients with NSCLC, whose tumors were diagnosed and tested for EGFR mutations at the University of Nebraska Medical Center (Omaha, NE) and Tata Memorial Hospital (Mumbai, India). Multivariate logistic regression was used to identify any association between EGFR status and clinical factors. Results EGFR mutations were more common in females than males (38.7% v 24.8%), Asians than whites (31.3% v 13.4%), nonsmokers than smokers (40.2% v 14.6%), alcohol nonconsumers than users (32.4% v 15.8%), adenocarcinoma than other histology types (32.7% v 10.3%), and patients with brain metastases than extracranial or no metastases (39.4% v 29.8% v 15.1%; P < .001 for all comparisons). There was a higher likelihood of an EGFR mutation among patients with brain metastases (odds ratio, 1.8; P < .001). The median overall survival (OS) was 19.8 months. Patients with brain metastases had a shorter median OS (15 v 20.6 months; P = .02). However, in the cohort of EGFR mutation–positive patients, there was no difference in median OS between patients with and without brain metastases (20.8 v 25.1 months; P = .11). Conclusion There is a nearly two-fold higher incidence of EGFR mutations in NSCLC among patients with brain metastases at diagnosis. EGFR mutations did not predict for outcomes from brain metastases.

Original languageEnglish (US)
Pages (from-to)208-217
Number of pages10
JournalJournal of Global Oncology
Volume3
Issue number3
DOIs
StatePublished - Jun 1 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Epidermal growth factor receptor mutational status and brain metastases in non–small-cell lung cancer'. Together they form a unique fingerprint.

Cite this